ArticleJournal of neuro-oncology2026
Neoadjuvant chemotherapy for pineal region tumors.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePineal region tumors are frequently large at diagnosis, often presenting with obstructive hydrocephalus. Surgical resection can be challenging due to intrinsic tumor vascularity and the surrounding eloquent neurovascular anatomy. For patients with large pineal region tumors, particularly young children, neoadjuvant chemotherapy may decrease both the size and vascularity of the tumor before definitive resection. Herein we present our experience.
methodsA single-center retrospective review of pediatric patients with pineal region/posterior third ventricular tumors was performed. Each patient received at least 2 rounds of neoadjuvant chemotherapy (carboplatin, etoposide, cyclophosphamide) prior to definitive resection. The primary outcome measure for this study was the radiographic effect of said chemotherapy on the tumor. Pre- and post-chemotherapy tumor volumes were calculated using magnetic resonance imaging tumor volume analytics. Secondary outcomes were estimated intraoperative blood loss, extent of resection, operative complications, readmission rates, and patient survival. Blood loss was calculated as a percentage of estimated total blood volume.
resultsWe identified thirty-one children and young adults (16 males, 15 females) who underwent neoadjuvant chemotherapy for pineal region tumors. The mean age of the population was 7.42 years (5 mo-22 yr). Pathologies were predominantly embryonal and included pineoblastoma (n=22; 71%), atypical teratoid rhabdoid tumor (n=5; 16%), pineal parenchymal tumor of intermediate differentiation (n=3; 10%), and embryonal tumor with multilayered rosettes (n=1; 3%). The average percent tumor volume reduction post chemotherapy was 51% (range, -12.4-90.0%); only 1 patient had an increase in tumor volume. There were no complications related to chemotherapy. All surgeries resulted in gross total or near total resections. Average blood loss as a percentage of preoperative total blood volume was 11.7% (1.1-38.8%). Average length of follow-up was 6.33 years (range, 1-14 years) with 20 patients (64.5%) alive at last follow-up.
conclusionsNeoadjuvant chemotherapy for certain pineal region tumors is a safe and effective means to decrease tumor volume. While we believe this reduction in tumor size facilitates subsequent resection, further multicenter studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.